Rolls-Royce Withdraws From Boeing NMA Race

Gemini Sparkle

Key Takeaways:

  • Rolls-Royce has withdrawn from the competition to power Boeing's proposed New Midsize Airplane (NMA).
  • The company cited an inability to meet the NMA's planned timeline, specifically regarding the rigorous testing required for its next-generation UltraFan engine.
  • Rolls-Royce will continue to develop the UltraFan engine, viewing it as foundational for future large civil aero engine programs.
  • The choice for the NMA powerplant is now narrowed down to options from CFM and Pratt & Whitney.
See a mistake? Contact us.

Image: Rolls-Royce

Rolls-Royce has removed itself from the competition to power Boeing’s proposed New Midsize Airplane (NMA) platform. The company announced on Thursday that while it believes the NMA platform complements Boeing’s existing product range, it isn’t able to commit to the planned timeline for the project. Rolls-Royce says it will continue to develop the next-generation UltraFan engine it had proposed for the NMA.

“UltraFan is the foundation of our future large civil aero engine programs and we must ensure that it has as smooth an entry into service as possible,” said Rolls-Royce President Chris Cholerton. “We had begun its development before the Boeing opportunity emerged and it must undergo a rigorous testing regime before we offer it to customers, which we do not believe can be achieved within the NMA timeframe.”

The choice for the NMA powerplant is now down to options from CFM and Pratt & Whitney. Boeing has previously said that the NMA, which was proposed in 2015, will be available in 225-seat and 275-seat versions with a range of between 4,500 and 5,000 NM. If Boeing elects to pursue the NMA project, the official launch is expected in 2020, with entry into service targeted for 2025.

Sign-up for newsletters & special offers!

Get the latest stories & special offers delivered directly to your inbox

SUBSCRIBE

Please support AVweb.

It looks like you’re using an ad blocker. Ads keep AVweb free and fund our reporting.
Please whitelist AVweb or continue with ads enabled.